The RNA inhibitor olpasiran significantly reduces a type of “bad cholesterol” that’s associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

RNA can act as an intermediary between the genome and the cell; active genes are transcribed into messenger RNA molecules, for example. While RNA can perform a variety of crucial functions, it is also ...

MILAN--(BUSINESS WIRE)--Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable cancers and genetic conditions, announces its launch and ...

K.M. Wassarman, R.M. Saecker, "Synthesis-mediated release of a small RNA inhibitor of RNA polymerase," Science, 314:1601-3, Dec. 3, 2006. "Besides confirming that the natural 6S RNA acts as a decoy by ...

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could crack intractable cancers. The Milan-based company was founded by RNA leaders ...

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...

Analysis could lead to future therapies to prevent deadly cardiac events. The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...